The pharmacogenetics of type 2 diabetes: a systematic review.
Maruthur NM, Gribble MO, Bennett WL, Bolen S, Wilson LM, Balakrishnan P, Sahu A, Bass E, Kao WH, Clark JM.
Maruthur NM, et al.
Diabetes Care. 2014;37(3):876-86. doi: 10.2337/dc13-1276.
Diabetes Care. 2014.
PMID: 24558078
Free PMC article.
Review.
Significant medication-gene interactions for glycemic outcomes included 1) metformin and the SLC22A1, SLC22A2, SLC47A1, PRKAB2, PRKAA2, PRKAA1, and STK11 loci; 2) sulfonylureas and the CYP2C9 and TCF7L2 loci; 3) repaglinide and the KCNJ11, SLC30A8, NEUROD1/BETA2, UC …
Significant medication-gene interactions for glycemic outcomes included 1) metformin and the SLC22A1, SLC22A2, SLC47A1, PRKAB2, PR …